Objective: Immunochemical detection of the protein p16INK4a in cervical cytology is used in combination with Ki-67. Cells positive for both proteins are certain to have been transformed by high-risk HPV. p16/Ki-67 immunocytochemistry provides a significant improvement in specificity over cytology and HPV DNA testing. However, p16/Ki-67 immunocytochemistry also has its limitations. Study Design: The research is based on the follow-up of 1,131 patients for whom p16/Ki-67 immunocytochemistry was performed with cytology. Dependencies on the age of patients with LSIL, number of p16/Ki-67-positive cells, and different results during repeated examinations were analyzed. Results: In LSIL, positive p16/Ki-67 is less specific for ≥CIN2/HSIL for patients younger than 30 years compared to patients aged 30 years or older (61.1 vs. 75.7%, p < 0.013). Using a score of 10 p16/Ki-67-marked cells as a positive result instead of 1 led to significantly higher specificity (89.0 vs. 70.2%, p < 0.001). This modified threshold offers better risk assessment in LSIL. In repeated immunocytochemical investigations, 28.4% of the results deviated from the first examination. Conclusion: The abovementioned discrepancies can be interpreted as hints about the molecular biological causes of suboptimal performance of p16/Ki-67. An efficient and reliable application of p16/Ki-67 immunocytochemistry requires knowledge of its methodological limitations.

Keywords:
Cervical cytology, p16, Ki-67, Biomarker, Methodical limitations, CIN
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.